• Eng
  • 中文
  • 日本語
  • Span
  • Eng
  • 中文
  • 日本語
  • Span
Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
2693-CL-0313

A study to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause

Astellas Study ID
2693-CL-0313
Clinicaltrials.gov ID
NCT06812754
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
CTR20250084
Get more information

Study summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can’t be used by all women or for as long as may be needed.

The goal of this study is to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause. This study will also confirm the safety of fezolinetant and how well the women cope with (tolerate) the treatment. The women will take 1 tablet of the study medicine either fezolinetant or placebo once a day for up to 12 weeks. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.

Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. During the study, the women will visit the study clinic several times. At each visit they will be asked if they had any medical problems. The women will have general safety checks. At some visits, a breast ultrasound (mammogram), cervical smear, and ultrasound of the womb (uterus) may be done.

The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or placebo).

Additional Study Details

Phase
Phase 2
Product
fezolinetant
Product
Fezolinetant
Placebo
Type
Interventional
Masking
Triple (Participant, Investigator, Outcomes Assessor)
Enrollment number
150
Show Additional Study Details

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A study to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi, China
    Contact Us
    Completed
    The second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Contact Us
    Completed
    Peking Union Medical College Hospital
    Beijing, Beijing, China
    Contact Us
    Completed
    Guangzhou Medical University - The Third Affiliated Hospital
    Guangzhou, Guangdong, China
    Contact Us
    Completed
    Xiangya Hospital, Central South University
    Zhuzhou, Hunan, China
    Contact Us
    Completed
    Shandong Provincial Hospital
    Jinan, Shandong, China
    Contact Us
    Completed
    Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan, China
    Contact Us
    Completed
    Southeast University, ZhongDa Hospital
    Nanjing, Jiangsu, China
    Contact Us
    Completed
    Nanjing First Hospital
    Nanjing, Jiangsu, China
    Contact Us
    Completed
    Guangxi Medical University (GXMU) - Liuzhou Renmin Hospital
    Liuzhou, Guangxi, China
    Contact Us
    Completed
    Hunan Provincial Maternal and Child Health Care Hospital
    Changsha, Hunan, China
    Contact Us
    Completed
    Shenzhen Maternal & Child Health Hospital
    Shenzhen, Guangdong, China
    Contact Us
    Completed
    Jilin Province FAW General Hospital
    Changchun, Jilin, China
    Contact Us
    Completed
    Shanxi Woman and Children Hospital
    Taiyuan, Shanxi, China
    Contact Us
    Withdrawn
    Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
    Contact Us
    Completed
    Beijing Hospital
    Beijing, Beijing, China
    Contact Us
    Completed
    Liuzhou Worker's Hospital
    Liuzhou, Guangxi, China
    Contact Us
    Completed
    The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin, China
    Contact Us
    Completed
    Capital Medical University (CMU) - Beijing Shijitan Hospital
    Beijing, Beijing, China
    Contact Us
    Completed
    The First hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Contact Us
    Completed
    Peking University Shenzhen Hospital
    Shenzhen, Guangdong, China
    Contact Us
    Completed
    Jinan Central Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong, China
    Contact Us
    Completed
    Hainan Women and Children's Medical Center
    Haikou, Hainan, China
    Contact Us
    Completed
    Capital Medical University - Beijing Obstetrics and Gynecology Hospital
    Beijing, Beijing, China
    Contact Us
    Completed
    Shanghai First Maternity and Infant Hospital
    Shanghai, Shanghai, China
    Contact Us
    Completed
    Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Contact Us
    Completed
    Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong, China
    Contact Us
    Trial info
    Follow Trial
    Age
    40 - 65 Years
    Diamond icon
    Condition
  • Hot Flashes
    • Gender icon
    Sex
    Female
    Calendar icon
    Trial Dates
    Mar 2025 - Feb 2026
    Additional Study Details
    Inclusion Criteria
    • Participant has a body mass index >/= 16 kg/m2 and
    • Participant must be seeking treatment or relief for vasomotor symptom(s) (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:
      • Spontaneous amenorrhea for >/= 12 consecutive months
      • Spontaneous amenorrhea for >/= 6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L); or
      • Having had bilateral oophorectomy >/= 6 weeks prior to the screening visit (with or without hysterectomy).
      • FSH > 40 IU/L if participants received hysterectomy but still have an ovary/ovaries.
    • Within the 10 days prior to randomization, participant must have a minimum average of 7 moderate to severe hot flash(es) (HFs) (VMS) per day (data must be available for at least 7 of the last 10 days prior to randomization).
    • Participant is in good general health as determined on the basis of medical history and general physical examination, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and electrocardiogram (ECG) within the reference range for the population studied, or showing no clinically relevant deviations.
    • Participant has documentation of a normal/negative or no clinically significant findings mammogram (or breast ultrasound) (e.g., < Breast Imaging-Reporting and Data System (BI-RADS) class 4; obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
    • Participant is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 12 (end of treatment (EOT)), and for participants who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit. This is not required for participants who have had a partial (supracervical) or total hysterectomy.
    • Participant has documentation of a normal or not clinically significant Pap test (or equivalent cervical cytology) within the previous 12 months of study enrollment or at screening. This is not required for participants who have had a total hysterectomy.
    • Participant has a negative urine pregnancy test at screening; this is not required for participants who have had a total hysterectomy.
    • Participant has a negative serology panel [i.e., negative hepatitis B surface antigen (HBsAg) and negative hepatitis C virus antibody (HCVAb) screens] at screening.
    • Participant agrees not to participate in another interventional study while participating in the present study.
    MaximizeExclusion Criteria
    • Participant has known substance abuse or alcohol addiction within 6 months of screening.
    • Participant has a current malignancy, with exception of non-metastatic basal cell carcinoma of the skin.
    • Participant has a history of malignancy with exceptions of at least 5 years post-treatment and without known recurrence.
    • For participants with a uterus: Participant has an unacceptable result from the TVU assessment at screening, i.e., full length of endometrial cavity cannot be visualized or presence of a clinically significant finding.
    • Participant has a history within the last 6 months of undiagnosed uterine bleeding.
    • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
    • Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of “yes” to question 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening [visit 1].
    • Participant has previously been enrolled in a clinical trial with fezolinetant or other neurokinin (NK) receptor antagonists.
    • Participant uses a prohibited therapy (strong and moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy (HRT), hormonal contraceptive or any treatment for VMS [prescription, over-the-counter, or herbal]) or is not willing to wash-out and discontinue use of such drugs for the full duration of study conduct.
    • Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
    • Participant has uncontrolled hypertension, defined as systolic blood pressure >/=140 mmHg or diastolic blood pressure as >/= 90 mmHg based on an average of 2 to 3 readings within the screening period.
      • Participants with a medical history of hypertension who are well controlled may be enrolled
      • Participants who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures
    • Participant has active liver disease, jaundice, elevated liver aminotransferases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST)), elevated total or direct bilirubin, elevated international normalized ratio (INR) or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 × upper limit of normal (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert’s syndrome with elevated total bilirubin (TBL) may be enrolled as long as hemolysis is ruled-out (i.e., direct bilirubin, hemoglobin and reticulocytes are normal).
    • Participant has creatinine > 1.5 × ULN; or estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula
    • Participant has a positive result for human immunodeficiency virus (HIV) at screening.
    • Participant has any condition which makes the participant unsuitable for study participation.
    • Participant is unable or unwilling to complete the study procedures.
    • Participant has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More